This study is examining whether a medicine called **ravulizumab** can help people with a kidney disease known as **Immunoglobulin A Nephropathy (IgAN)**. People with IgAN sometimes have too much protein in their urine, which can be a sign that their kidneys aren’t working well. The study will compare ravulizumab to a **placebo** (a treatment that doesn’t contain any active medicine). Participants will receive the treatment through an **IV infusion**, which means the medicine goes directly into their vein. The study will last until Week 106, and there will be an interim analysis at Week 34.

• Participation involves regular visits and receiving an IV infusion.
• The study includes around 450 participants and takes about 2 years to complete.
• Participants have the option to continue receiving ravulizumab after the study ends.

People with certain conditions such as active infections, other kidney diseases, or a history of kidney transplant may not be eligible to join. If you have IgAN and meet the study criteria, you might consider participating in this study to potentially benefit from the treatment and help advance medical research.